RxDoctor Payments Data

Abigail Wiseley, PA

Physician Assistant · Cumming, GANPI 1871131086

Payments from drug & device makers

$10,052in general payments, 2019–2025

Across 399 payments — averaging $25.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Sanofi$1K
  • UCB, Inc.$887
  • Sun Pharmaceutical Industries Inc.$656
  • Arcutis Biotherapeutics, Inc.$573
  • plus $4K from 35 others
$1,580in research payments, 2019–2025

Across 10 payments — averaging $157.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$2K

What the payments were for

  • Food & beverage$9,66696%
  • Education$3874%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,052 in reported general payments places this provider in the 95th percentile of 3,581 physician assistant providers in Georgia.

See all physician assistant providers in Georgia

Medicare billing

Part B allowed, 2024
$67,413
Medicare patients
287
Services billed
1,881

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab39$136,548
RinvoqUpadacitinib11$67,275
AdbryTralokinumab-Ldrm12$44,787
Ketoconazole190$2,743
Clobetasol Propionate93$2,629
Fluorouracil25$1,671
Tacrolimus17$1,519
Metronidazole24$1,490
Tretinoin16$1,405
Clindamycin Phosphate35$1,022
Fluocinonide21$836
Triamcinolone Acetonide77$432
Betamethasone Dipropionate11$369
ValacyclovirValacyclovir Hcl13$256
Mupirocin37$225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$1,370$67,27511 claims
LEO Pharma Inc.Adbry$464$44,78712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,581 physician assistant providers in Georgia.

Other physician assistant in Cumming

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →